title: CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation.
abstract: Myelodysplasia (MDS) is mostly characterized by a normal or increased number of normoblasts in the bone marrow and an impaired in vitro colony formation. In the present study we analyzed whether this might be due to a disconnection between proliferation and differentiation. CD34+/CD36- sorted bone marrow cells of 18 MDS patients were cultured in a clonogenic and suspension culture assay in the presence of erythropoietin (Epo) and mast cell growth factor (MGF). Burst-forming units erythroid (BFU-E, 75 +/- 88/10(4) CD34+ cells, X +/- s.d.) and colony-forming units E (CFU-E) were observed in eight of the 13 cases (62%) with refractory anemia with or without ring sideroblasts (RA and RARS) and one of the five cases with RA with excess of blasts or in transformation (RAEB and RAEB-T). Suspension cultures with CD34+/CD36- sorted cells with Epo plus MGF demonstrated an 8.9 +/- 6.5-fold expansion after 7 days in cases with >10 BFU-E/10(4) CD34+/CD36- cells while cases with <10 BFU-E/10(4) CD34+/CD36- cells demonstrated 1.0 +/- 0.8-fold expansion especially in cases with RAEB/RAEB-T. FACS and morphology analysis after 7 days of suspension culture demonstrated partial differentiation along the erythroid lineage in cases with RA/RARS (75%) and RAEB/RAEB-T (66%) reflected by the presence of erythroblasts and normoblasts with variable expression of CD34, CD36 and Glycophorin A. In cases with erythroid colony formation 69 +/- 24% of the cells were CD34-/CD36+ and in cases with <10 BFU-E/10(4) CD34+ cells 18 +/- 16% of cells were CD34-/CD36+. Iron staining showed the presence of ring sideroblasts in two cases with RARS indicating that the cells originate from the abnormal erythroid clone. Finally, it was shown that cases with an impaired proliferative response demonstrate an enhanced binding of Annexin-V on CD34+ cells during the first days of the cell suspension culture phase. These results suggest that a defect in the proliferative response is most pronouncedly expressed in MDS whereas a subpopulation of cells retain the capacity to differentiate between transition to a terminated stage.
authors.affiliation: Department of Hematology, University Hospital Groningen, The Netherlands.
authors.forename: S J
authors.initials: SJ
authors.lastname: Brada
authors.forename: J T
authors.initials: JT
authors.lastname: de Wolf
authors.forename: D W
authors.initials: DW
authors.lastname: Hendriks
authors.forename: J W
authors.initials: JW
authors.lastname: Smit
authors.forename: E
authors.initials: E
authors.lastname: Vellenga
mesh_terms: D000753:Anemia, Refractory / Q000097:blood*; D018952:Antigens, CD34 / Q000032:analysis*; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000502:physiology; D018955:CD36 Antigens / Q000032:analysis*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D015672:Erythroid Precursor Cells / Q000187:drug effects* / Q000502:physiology; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D019089:Stem Cell Factor / Q000494:pharmacology*
chemical_list: D018952:Antigens, CD34; D018955:CD36 Antigens; D019089:Stem Cell Factor; D004921:Erythropoietin